Holen Sie sich die Stockscreener-App
50.21
50.55%
-51.32
Grail Inc Aktie (GRAL) Neueste Nachrichten
Grail’s Cancer Detection Test Fails in Major Study — What It Means for the Future of Early Cancer Screening - vocal.media
GRAIL Stock: A Major Trial Disappointment (NASDAQ:GRAL) - Seeking Alpha
GRAIL (-51%): NHS-Galleri Trial Misses Primary Endpoint, Erasing Value - Trefis
Grail Trial Setback Raises Questions Over Multi-Cancer Blood Screening Outlook - TipRanks
TD Cowen reiterates Hold on Grail stock after study setback By Investing.com - Investing.com Nigeria
Grail Shares Crashes 50% After Major Cancer Screening Trial Fails Main Goal - GuruFocus
5 Analysts Assess GRAIL: What You Need To Know - Benzinga
This once-hot cancer-detection company’s stock got cut in half after a failed trial - MarketWatch
These Stocks Are Today’s Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More - Barron's
Grail Stock Is Deeply Oversold on Cancer Test Failings. Is There Any Hope Left to Buy the Dip? - Yahoo Finance
Grail’s Galleri Blood Test Falls Short in Large Cancer-Screening Study, Shares Sink 50% - MedCity News
Grail’s multi-cancer early detection test misses study goal - BioPharma Dive
Trouble Continues for Grail as Stock Falls After Cancer Blood Test Trial Fails to Meet Endpoint - Medical Device and Diagnostic industry
Grail, Corning, Comfort Systems USA, Opendoor, Akamai, and More Market Movers - Barron's
After rallying, Grail's cancer test faces new uncertainty due to UK study - Endpoints News
GRAL ALERT: Investigation Launched into GRAIL, Inc., RGRD - GlobeNewswire
GRAL ALERT: Investigation Launched into GRAIL, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - GlobeNewswire Inc.
GRAIL stock dives nearly 50% after UK Galleri trial misses key goal, raising FDA questions - TechStock²
Here's Why Grail Stock Crashed 50% Today - Yahoo Finance
Key Study of Grail’s Cancer Detection Test Fails in Setback for Company - vocal.media
Why Grail Stock Has Plunged 50% Despite Earnings Beat - Barron's
Grail Stock Plunges 50% After Earnings. Test Results Are to Blame. - Barron's
These Stocks Are Today’s Movers: Grail, Corning, Opendoor, Akamai, AppLovin, Chemours, and More - Barron's
Grail shares plummet after UK study raises doubts over cancer test's prospects - marketscreener.com
Baird Lowers Price Target for GRAIL (GRAL) to $82, Maintains Out - GuruFocus
Canaccord Genuity cuts Grail stock price target on trial results By Investing.com - Investing.com India
Relative Strength Alert For Grail - Nasdaq
GRAIL Inc (GRAL) Trading Down 46.11% on Feb 20 - GuruFocus
Grail shares plunge after Galleri test misses primary endpoint - BioWorld MedTech
These stocks are today’s movers: Grail, AppLovin, Nvidia, Opendoor, Akamai, Newmont, Copart, and more - MSN
Grail shares plummet after cancer test falls short in three-year NHS study - FirstWord Pharma
Grail, Wayfair, Crocs, AppLovin, Opendoor, Akamai, Newmont, and More Market Movers - Barron's
Grail shares sink after cancer-screening trial disappointment - Sharecast.com
Stock market today: Dow Jones, S&P 500 futures rise ahead of Q4 GDP numbers—Grail, Candel Therapeutics, Copart in focus - MSN
Biotech Stock Plummets on Cancer Screening Trial Results - Schaeffer's Investment Research
TD Cowen reiterates Hold on Grail stock after study setback - Investing.com
Grail (GRAL) Stock Crashes as Q4 Earnings Beat Overshadowed by Cancer Trial Results - parameter.io
GRAIL's NHS-Galleri Trial Falls Short Of Primary Endpoint In Multi-Cancer Screening, Shares Slide - Nasdaq
Element Biosciences launches table-top sequencer capable of $100 genome - statnews.com
Canaccord Genuity cuts Grail stock price target on trial results - Investing.com
Stock Movers: Blue Owl, Grail, Opendoor - Bloomberg
Pharmalittle: We're reading about an FDA official's speech, a Grail cancer blood test, and much more - statnews.com
Cancer Test Company Stock Crashes After Clinical Trial Falls Short - Fine Day 102.3
Grail’s Cancer Detection Test Fails in Major Study - The New York Times
Grail tanks after cancer detection test fails in key study - Sherwood News
GRAL Inc. Faces Market Volatility Amid Earnings Announcement - timothysykes.com
Stock Market Today: Dow Jones, S&P 500 Futures Slip After Weaker-Than-Expected GDP Report—Grail, Candel Therapeutics, Copart In Focus (UPDATED) - Benzinga
Grail (GRAL) Stock: Why the Biotech Crashed 50% Overnight - Blockonomi
Grail shares plunge after major cancer screening trial misses main goal - marketscreener.com
Grail's multi-cancer test fluffs its lines in UK trial - pharmaphorum
Analysis of Stock Price Movements for Multiple Companies - Intellectia AI
Stock Market Today: Dow Falls Ahead Of Trump Tariff Decision; Grail Crashes After Test Results (Live Coverage) - Investor's Business Daily
GRAIL Stock Tumbles Despite EPS Beat After Cancer Trial Miss - Tokenist
Grail Stock Plunges 46% After Earnings. Test Results Are to Blame. - Barron's
Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone - Stocktwits
US Premarket Movers: Akamai, Grail, Hudbay, Newmont, Opendoor - Bloomberg.com
Grail stock craters as Galleri trial fails to hit endpoint - Fierce Biotech
Stocks making the biggest moves premarket: Grail, Blue Owl Capital, Opendoor Technologies & more - CNBC
Grail (GRAL) Stock Crashes 50% After NHS Cancer Trial Misses Primary Endpoint - CoinCentral
GRAIL stock tumbles nearly 48% premarket after Galleri trial miss — what GRAL investors watch next - Bez Kabli
Opendoor, Nvidia, Grail, Newmont, AppLovin, and More Stock Market Movers - Barron's
GRAIL Q4 2025 Earnings Call Transcript - MarketBeat
Why Grail Stock Is Sinking Friday - Bitget
Stock Market Today: Dow Jones, S&P 500 Futures Rise Ahead Of Q4 GDP Numbers-Grail, Candel Therapeutics, Copart In Focus - Bitget
0.01%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):